Achromatopsia Clinical Trials 2023

What are the top hospitals conducting achromatopsia research?

When it comes to advancing research and treatment options for achromatopsia, a rare genetic condition that affects the ability to perceive colors, several esteemed hospitals are leading the way. In San Francisco, the University of California, San Francisco (UCSF) has emerged as a pioneer in this field with two ongoing clinical trials dedicated to achromatopsia. UCSF's commitment began in 2016 when they recorded their first trial on this condition. Similarly, at the prestigious McPherson Eye Research Institute within the University of Wisconsin in Madison, researchers are actively engaged in two clinical trials for achromatopsia—a testament to their dedication and expertise since commencing studies on this disorder also back in 2016.

On the other side of Texas lies San Antonio's University of Incarnate Word Rosenberg School of Optometry—an institution making waves within the medical community due to its recent involvement with achromatopsia research. With one active clinical trial currently underway and having recorded their inaugural study just last year (2022), they demonstrate promising progress.

The Edward S. Harkness Eye Institute located in New york City is another prominent hospital committed to unraveling the mysteries surrounding achromatopsia. Currently undertaking an active clinical trial alongside their previous investigation—both dating from 2023—they strive towards finding innovative solutions for those affected by this visually impairing condition.

Finally, situated in Ann Arbor is Kellogg Eye Center—a renowned facility known not only for its excellence but also its dedication towards transforming lives through cutting-edge research and care provision. Having initiated their first-ever trial on achromatopsia back in 2017—the same year as recording their sole ongoing study—they have made significant contributions towards understanding and managing this rare genetic affliction.

These distinguished hospitals signify that although achromatopsia may be relatively uncommon, there exists a global collaboration among experts who tirelessly work together across various locations and disciplines to bring hope and progress to individuals affected by this condition. Through their collective efforts, they aim to improve the quality of life for those living with achromatopsia while advancing our knowledge and treatment options in the realm of rare genetic disorders.

Which are the best cities for achromatopsia clinical trials?

When it comes to achromatopsia clinical trials, several cities have emerged as prominent locations for research. San Francisco, California, Boston, Massachusetts, and Madison, Wisconsin each offer two active trials focused on treatments like AGTC-402 and rAAV2tYF-PR1.7-hCNGB3. Additionally, San Antonio, Texas hosts one trial examining the effectiveness of color correcting lenses. New york City also contributes to the field with a single ongoing trial investigating PBA and other potential solutions. These cities serve as key hubs for individuals seeking participation in cutting-edge achromatopsia clinical trials that hold promise for improved vision and quality of life.

Which are the top treatments for achromatopsia being explored in clinical trials?

Exciting developments are underway in the realm of achromatopsia treatment, with several key options being explored through clinical trials. These include:

• Experimental Group 1: Color Correcting Lenses, currently involved in one active trial for achromatopsia since its first listing in 2022.
• PBA (Phosducin-like protein variant), also participating in one ongoing trial dedicated to achromatopsia and introduced to clinical trials in 2023.

Additionally, there are four more potential treatments showing promise:

• AAV - CNGB3 or AAV - CNGA3 gene therapies have each entered one active trial for achromatopsia after their initial listings respectively in 2017.
• AGTC-402 is another promising option engaged in one active trial since it was listed as a potential treatment for achromatopsia back in 2017.
• rAAV2tYF-PR1.7-hCNGB3 rounds out the list with its participation in an ongoing trial focused on treating this condition following its introduction to clinical trials back in 2016.

With ongoing research and advancement, these treatments offer hope for those affected by achromatopsia.

What are the most recent clinical trials for achromatopsia?

Exciting advancements in clinical trials offer hope to individuals living with achromatopsia, a rare and debilitating vision disorder. Among the recent trials is AGTC-402, which has progressed into Phase 1 and Phase 2 studies since its availability on August 3, 2017. Additionally, promising research focuses on two other potential treatments: AAV-CNGB3 or AAV-CNGA3 for achromatopsia. These therapies have reached Phase 1 and Phase 2 stages following their availability on June 29, 2017. Another trial worth mentioning explores rAAV2tYF-PR1.7-hCNGB3 for achromatopsia; this treatment entered Phases 1 and 2 after becoming available on April11, 2016. Together, these groundbreaking studies bring renewed optimism to those affected by achromatopsia as they move closer towards potentially life-changing treatments.

What achromatopsia clinical trials were recently completed?

Several clinical trials focused on achromatopsia have recently concluded, representing significant advancements in the field. These studies aimed to address this inherited retinal disorder characterized by color blindness and reduced visual acuity. Notably, a trial sponsored by ProQR Therapeutics reached completion in June 2021, showcasing promising outcomes for their novel therapeutic approach. Additionally, MeiraGTx Holdings successfully completed their own clinical trial investigating gene therapy as a potential treatment for achromatopsia. These recent milestones highlight the ongoing efforts to find effective interventions for individuals affected by this visually impairing condition.